PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
PHXM was delisted on the 8th of March, 2024.
8 hedge funds and large institutions have $85.7K invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
11% less funds holding
Funds holding: 9 → 8 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
77% less capital invested
Capital invested by funds: $374K → $85.7K (-$289K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$21.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$216K |
| 2 |
VF
Virtu Financial
New York
|
-$20K |
| 3 |
Millennium Management
New York
|
-$16.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$539 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VPIM
1
Vanguard Personalized Indexing Management
Oakland,
California
| $18.7K | – | – | – |
|
2
Mariner
Overland Park,
Kansas
| $18.4K | – | – | – |
|
|
BBA
3
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| $14.7K | +$21.1K | +2,400 | New |
|
|
4
Citadel Advisors
Miami,
Florida
| $12.1K | +$5.1K | +580 | +54% |
|
|
5
Millennium Management
New York
| $8.81K | -$16.5K | -1,873 | -61% |
|
6
Group One Trading
Chicago,
Illinois
| $7.73K | – | – | – |
|
|
ADL
7
Asset Dedication LLC
San Francisco,
California
| $3K | – | – | – |
|
|
IC
8
Ikarian Capital
Dallas,
Texas
| $2.26K | -$216K | -24,541 | -99% |
|
|
VF
9
Virtu Financial
New York
| – | -$20K | -2,003 | Closed |
|
|
10
UBS Group
Zurich,
Switzerland
| – | -$539 | -55 | Closed |
|
PHXM Hedge Fund Activity: Q2 2023 in Review
8 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q2 2023, worth a combined $85.7K — down 77% from $374K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PHXM and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Baader Bank Aktiengesellschaft, opening a new position worth an estimated $21.1K. The largest seller was Ikarian Capital, cutting an estimated $216K.
- 8 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q2 2023, down from 9 in Q1 2023.
- Funds reported $85.7K of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q2 2023, down 77% quarter-over-quarter.
- 1 fund opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q2 2023 and 2 closed out, a net change of -1 holder.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q2 2023 was Baader Bank Aktiengesellschaft, an estimated $21.1K added.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q2 2023 was Ikarian Capital, an estimated $216K sold.
Based on aggregated 13F filings for Q2 2023.